Lawrence Berry, MA, LCMHC Psychologist Medicare: Not Enrolled in Medicare Practice Location: 154 Duchess Ave, Newport, VT 05855 Phone: 802-334-6744 |
Tanya Rexford Searles, MA Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 194 Main St, Suite 210, Newport, VT 05855 Phone: 802-334-6280 |
Dr. Karen J Hack Psychologist Medicare: Not Enrolled in Medicare Practice Location: 154 Duchess St, Newport, VT 05855 Phone: 802-334-6744 Fax: 802-334-7455 |
Neila A Anderson-decelles, MA Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 215 Glen Rd, Newport, VT 05855 Phone: 802-334-7578 |
Daniel G Griffes, MA Psychologist Medicare: Not Enrolled in Medicare Practice Location: 194 Main St, Suite 109, Newport, VT 05855 Phone: 802-334-7549 Fax: 704-987-4449 |
Douglas Alan Flint, M.S. LICENSED PSYCHO Psychologist - Group Psychotherapy Medicare: Accepting Medicare Assignments Practice Location: 494 Highland Ave Ste B, Newport, VT 05855 Phone: 802-334-1795 Fax: 802-334-1795 |
Judy D Young, MA Psychologist Medicare: Not Enrolled in Medicare Practice Location: 154 Duchess Ave, Newport, VT 05855 Phone: 802-334-7451 Fax: 802-334-7340 |
Sharon Steadman, MA Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 31 Canvas Back Ln, Newport, VT 05855 Phone: 801-386-6500 |
News Archive
Anti-inflammatory drugs appear to help block the rapid kidney destruction that can occur with hypertension, Medical College of Georgia researchers report.
Scientists are reporting a possible explanation for the bone loss that may occur following long-term use of a medicine widely used to treat epilepsy, bipolar disorder, and other conditions. The drug, valproate, appears to reduce the formation of two key proteins important for bone strength, they said. Their study, which offers a solution to a long-standing mystery, appears in ACS' monthly Journal of Proteome Research.
Pharmaceutical companies GlaxoSmithKline and Pfizer today announced an "innovative agreement" to pool their HIV assets creating a new world-leading, specialist HIV company.
Scientists at Biocontrol, leading the world in developing new treatments to cure serious antibiotic-resistant infections, have secured a £250,000 investment from The Capital Fund.
› Verified 6 days ago